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Abstract
BACKGROUND—Randomized-trial data on the risks and benefits of antiretroviral therapy 
(ART) as compared with zidovudine and single-dose nevirapine to prevent transmission of the 
human immunodeficiency virus (HIV) in HIV-infected pregnant women with high CD4 counts are 
lacking.
METHODS—We randomly assigned HIV-infected women at 14 or more weeks of gestation with 
CD4 counts of at least 350 cells per cubic millimeter to zidovudine and single-dose nevirapine 
plus a 1-to-2-week postpartum “tail” of tenofovir and emtricitabine (zidovudine alone); 
zidovudine, lamivudine, and lopinavir–ritonavir (zidovudine-based ART); or tenofovir, 
emtricitabine, and lopinavir–ritonavir (tenofovir-based ART). The primary outcomes were HIV 
transmission at 1 week of age in the infant and maternal and infant safety.
RESULTS—The median CD4 count was 530 cells per cubic millimeter among 3490 primarily 
black African HIV-infected women enrolled at a median of 26 weeks of gestation (interquartile 
range, 21 to 30). The rate of transmission was significantly lower with ART than with zidovudine 
alone (0.5% in the combined ART groups vs. 1.8%; difference, −1.3 percentage points; repeated 
confidence interval, −2.1 to −0.4). However, the rate of maternal grade 2 to 4 adverse events was 
significantly higher with zidovudine-based ART than with zidovudine alone (21.1% vs. 17.3%, 
P=0.008), and the rate of grade 2 to 4 abnormal blood chemical values was higher with tenofovir-
based ART than with zidovudine alone (2.9% vs. 0.8%, P=0.03). Adverse events did not differ 
significantly between the ART groups (P>0.99). A birth weight of less than 2500 g was more 
frequent with zidovudine-based ART than with zidovudine alone (23.0% vs. 12.0%, P<0.001) and 
was more frequent with tenofovir-based ART than with zidovudine alone (16.9% vs. 8.9%, 
P=0.004); preterm delivery before 37 weeks was more frequent with zidovudine-based ART than 
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with zidovudine alone (20.5% vs. 13.1%, P<0.001). Tenofovir-based ART was associated with 
higher rates than zidovudine-based ART of very preterm delivery before 34 weeks (6.0% vs. 2.6%, 
P=0.04) and early infant death (4.4% vs. 0.6%, P=0.001), but there were no significant differences 
between tenofovir-based ART and zidovudine alone (P=0.10 and P=0.43). The rate of HIV-free 
survival was highest among infants whose mothers received zidovudine-based ART.
CONCLUSIONS—Antenatal ART resulted in significantly lower rates of early HIV transmission 
than zidovudine alone but a higher risk of adverse maternal and neonatal outcomes. (Funded by 
the National Institutes of Health; PROMISE ClinicalTrials.gov numbers, NCT01061151 and 
NCT01253538.)
Antiretroviral regimens used for the prevention of mother-to-child transmission of the 
human immunodeficiency virus (HIV) have evolved from the first successful trial that used 
zidovudine single-drug prophylaxis in 1994 to current triple-drug regimens.1,2 Although 
there are clear benefits of combination antiretroviral therapy (ART) for the mother and 
infant, these do not come without risks; some studies have shown higher rates of adverse 
pregnancy outcomes with maternal ART than with regimens containing fewer antiretroviral 
agents.3–5 The Promoting Maternal and Infant Survival Everywhere (PROMISE) trial 
compared the relative efficacy and safety of various proven antiretroviral strategies for the 
prevention of mother-to-child transmission during pregnancy among asymptomatic HIV-
infected pregnant women with high CD4 counts. Results evaluating early transmission 
through the week 1 postpartum trial visit (in utero, intrapartum, or very early breast-feeding 
transmission) are presented.
METHODS
TRIAL SITES AND PARTICIPANTS
The PROMISE trial was conducted at 14 sites in seven countries (India, Malawi, South 
Africa, Tanzania, Uganda, Zambia, and Zimbabwe). When enrollment began in 2011, 
standard prevention of mother-to-child transmission for women with a CD4 count of more 
than 350 cells per cubic millimeter in these countries was zidovudine with intrapartum 
single-dose nevirapine and a 1-to-2-week “tail” of two nucleosides to prevent maternal 
nevirapine resistance.6
Eligibility criteria included a CD4 count of at least 350 cells per cubic millimeter (or a 
country-specific threshold for initiating triple-drug ART, if that threshold was higher), 
gestation of at least 14 weeks and not in labor, no previous use of triple-drug ART, no 
clinical or immune-related indication for triple-drug ART, a hemoglobin level of at least 7.5 
g per deciliter, an absolute neutrophil count of at least 750 cells per cubic millimeter, an 
alanine aminotransferase level of less than 2.5 times the upper limit of the normal range, an 
estimated creatinine clearance of more than 60 ml per minute, and no serious pregnancy 
complications. Receipt of one or two antiretroviral agents for the prevention of mother-to-
child transmission in previous pregnancies and for 30 days or fewer during the current 
pregnancy before enrollment was permitted. Key exclusion criteria were active tuberculosis 
or receipt of tuberculosis treatment within 30 days before trial entry, hepatitis B virus (HBV) 
infection requiring HBV treatment (patients who did not require HBV treatment could 
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enroll), a structural or conduction heart defect, or a fetus with a serious congenital 
malformation.
All pregnant women provided written informed consent. The trial was approved by local and 
collaborating institutional review boards and reviewed every 6 months by an independent 
data and safety monitoring board (members are listed in the Supplementary Appendix, 
available with the full text of this article at NEJM.org).
TRIAL DESIGN AND TREATMENT REGIMENS
The PROMISE trial compared open-label strategies and included sequential randomizations: 
antepartum randomization (at 14 weeks of gestation or later) to one of three regimens, with 
postpartum randomization (breast-feeding settings) at 6 to 14 days to maternal ART or infant 
prophylaxis during breast-feeding and “maternal health” randomization of women receiving 
ART to continue or stop ART after breast-feeding cessation or birth (formula-feeding 
settings). Breast-feeding settings (enrollment started in April 2011) and formula-feeding 
settings (enrollment started in July 2011) had separate protocols (available at NEJM.org); 
the complete PROMISE trial schema is shown in Figure S1A and S1B in the Supplementary 
Appendix. At the November 2014 planned interim analysis, the prespecified early stopping 
guideline for efficacy for the antepartum component was met, and the data and safety 
monitoring board recommended releasing the results.
In the antepartum component, women were randomly assigned to one of three regimens: 
zidovudine plus intrapartum single-dose nevirapine with 6 to 14 days of tenofovir and 
emtricitabine post partum (zidovudine alone); zidovudine, lamivudine, and lopinavir–
ritonavir (zidovudine-based ART); or tenofovir, emtricitabine, and lopinavir–ritonavir 
(tenofovir-based ART). All regimens were continued through 6 to 14 days post partum. All 
infants received nevirapine from birth until postpartum randomization. Figure 1 shows the 
antepartum regimens and dosing.
Antiretroviral agents were donated by AbbVie, Boehringer Ingelheim, Gilead Sciences, and 
ViiV Healthcare/GlaxoSmithKline, with the exception that some nevirapine was purchased 
from Boehringer Ingelheim at a discounted rate by a contractor to the Eunice Kennedy 
Shriver National Institute of Child Health and Human Development for use in the trial. None 
of the pharmaceutical companies had any role in the trial design, data collection, data 
analyses, or manuscript preparation.
When the trial began, there were limited safety data on tenofovir in pregnancy, and 
randomization to tenofovir-based ART was limited to women coinfected with HIV and 
HBV, because benefit was felt to outweigh risk in that group; comparative analyses 
including the group assigned to tenofovir-based ART were to be limited to a nested HBV 
substudy. During period 1 (April 2011 through September 2012), women without HBV 
coinfection were assigned only to zidovudine alone or zidovudine-based ART. However, in 
October 2012, with increased data on tenofovir in pregnancy, the protocol was modified to 
allow women regardless of HBV status to be assigned to any of the three regimens, with an 
analytic plan to compare safety across all three groups for participants enrolled during 
period 2 (October 2012 through October 1, 2014).
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TRIAL PROCEDURES
Screening included confirmation of maternal HIV status and measurement of the CD4 count 
and HBV surface antigen (HBsAg) level. Maternal visits occurred at trial entry; at weeks 2, 
4, 8, and 12 and then every 4 weeks until delivery; at labor and delivery; and at postpartum 
week 1 (6 to 14 days). A complete blood count and blood chemical values (alanine 
aminotransferase and creatinine levels and calculated creatinine clearance) were obtained at 
trial entry; at weeks 4, 8, and 12 and then every 8 weeks; at delivery; and at postpartum 
week 1. The plasma HIV RNA concentration (quantified by real-time polymerase-chain-
reaction assay in the ART groups and by batch testing of stored samples in the zidovudine-
alone group) was measured at trial entry, week 4, and delivery or postpartum week 1. The 
CD4 count was obtained at week 12, delivery, and postpartum week 1. Infant visits, 
including HIV nucleic acid testing and measurement of safety laboratory values, occurred at 
birth (to 5 days of age) and week 1 (6 to 14 days of age). Full details are provided in the 
protocol.
EFFICACY AND SAFETY OUTCOMES
Early infant HIV infection, the primary efficacy outcome, was defined as a positive infant 
HIV nucleic-acid-testing result on the birth or week 1 specimen, confirmed by a second 
positive result on a separate specimen obtained on a different day (as soon as possible after 
the first positive result); tests were performed in laboratories that were certified by the 
Virology Quality Assurance Program of the Division of AIDS (DAIDS) of the National 
Institute of Allergy and Infectious Diseases. Infant HIV-free survival, a secondary safety 
outcome, was defined as an infant being alive and not HIV-infected through the week 1 visit.
The DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events was used 
to grade adverse events.7 Primary safety analyses were composite, with secondary analysis 
of individual components. For mothers, the composite outcome was grade 2 or higher 
hematologic abnormalities or abnormal blood chemical values or grade 3 or higher signs or 
symptoms during pregnancy through week 1 post partum. For pregnancy, the composite 
outcome was a low birth weight of less than 2500 g, a preterm delivery before 37 weeks of 
gestation (according to the Ballard examination, when available, or obstetrical estimate), 
spontaneous abortion (<20 weeks of gestation), stillbirth (≥20 weeks of gestation), or a 
congenital anomaly (according to the criteria of the Metropolitan Atlanta Congenital Defects 
Program of the Centers for Disease Control and Prevention). Severe adverse pregnancy 
outcomes included a very low birth weight of less than 1500 g, a very preterm delivery 
before 34 weeks, spontaneous abortion, stillbirth, or a major congenital anomaly. For 
infants, the composite outcome was death from any cause, grade 3 or higher hematologic 
abnormalities or abnormal blood chemical values, or grade 3 or higher signs or symptoms 
through week 1 post partum.
TRIAL ROLES
The PROMISE trial was designed by the protocol team, with the first author and the 
cochairs taking the lead. The clinical sites gathered the data; the International Maternal 
Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT) Statistical and Data 
Analysis Center at the Harvard T.H. Chan School of Public Health analyzed the data 
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according to the agreed-on statistical plans and with input from the protocol team and the 
data and safety monitoring board. All the authors vouch for the completeness and accuracy 
of the data and analyses and for the fidelity of the trial to the protocol.
STATISTICAL ANALYSIS
Randomization was stratified according to HBV status and country. The target sample was 
4400 mother–infant sets, 3400 from breast-feeding settings and 1000 from formula-feeding 
settings, to be combined for analysis. We calculated that this sample size would provide the 
trial with more than 90% power to detect a cumulative early transmission difference of 4% 
in the zidovudine-alone group versus 2% in the two ART groups combined, with a 5% (two-
sided) type I error, allowing for 10% loss to follow-up and two interim efficacy analyses, and 
95% power to detect differences as small as 25% versus 20% for safety outcomes.
The a priori analysis plan required combining the results of the two ART groups for efficacy 
analyses because efficacy was expected to be similar. However, because adverse events were 
expected to differ between ART groups, safety analyses (including HIV-free survival 
through week 1) were to include pairwise comparisons of all three groups.
Safety comparisons of the zidovudine-alone group and the group assigned to zidovudine-
based ART were based on data from both period 1 and period 2. Pairwise safety 
comparisons of the group assigned to tenofovir-based ART with the zidovudine-alone group 
or the group assigned to zidovudine-based ART were restricted to data from participants 
enrolled during period 2, when there was concurrent randomization to all three groups. All 
analyses were conducted on an intention-to-treat basis. The unit of analysis was the mother–
infant set for efficacy analyses and the individual participant (mother or infant) for safety 
analyses. For multiple-gestation births, perinatal transmission was defined as confirmed HIV 
infection in any of the live-born siblings; for infant safety analyses, each live-born sibling 
was included separately.
Categorical variables were compared between groups with Fisher’s exact test. A two-sided P 
value of less than 0.05 was considered to indicate statistical significance for all analyses 
except efficacy. Interim efficacy analyses used a group-sequential repeated confidence 
interval for the difference in the early transmission rate with the use of the Lan–DeMets 
approach with an O’Brien–Fleming type I error spending function (for this interim analysis, 
the confidence coefficient was 96.5%, to preserve an experiment-wise type I error rate of 
5%). If the repeated confidence interval excluded zero, this would indicate a significant 
difference. One prespecified subgroup analysis and two post hoc subgroup analyses were 
performed, with interaction tests assessing heterogeneity of treatment effects.
RESULTS
BASELINE MATERNAL CHARACTERISTICS
From April 2011 through September 10, 2014 (the cutoff date for the interim analysis), we 
enrolled 3529 mother–infant sets (3245 in breast-feeding settings and 284 in formula-
feeding settings). A total of 39 women were excluded from analyses: 3 were determined not 
Fowler et al. Page 5
N Engl J Med. Author manuscript; available in PMC 2017 May 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
to be pregnant at enrollment, 2 had molar pregnancies, and 34 were coinfected with HIV and 
HBV and were randomly assigned to receive tenofovir-based ART during period 1.
Of the 3490 mother–infant sets included in analyses, 2261 (65%) were enrolled during 
period 1 and 1229 (35%) during period 2. There were 3202 live births (1045 during period 
2), including 57 multiple births with at least 1 live-born infant (24 during period 2). The 
numbers and flow of participants in the trial are shown in Figure S2A (randomization to 
zidovudine alone or zidovudine-based ART in periods 1 and 2) and Figure S2B 
(randomization to zidovudine alone, zidovudine-based ART, or tenofovir-based ART in 
period 2 only) in the Supplementary Appendix.
Baseline maternal characteristics were well balanced between the zidovudine-alone group 
and the group assigned to zidovudine-based ART (periods 1 and 2) and between the group 
assigned to tenofovir-based ART and each of the other two trial groups (period 2) (Table 1; 
Table S1 in the Supplementary Appendix provides further details on CD4 cell count and 
viral-load quantification according to group). There were differences between periods 1 and 
2 in country-specific enrollment (higher during period 1 in South Africa and during period 2 
in Zimbabwe and Uganda) and in the percentage of women receiving zidovudine alone 
during the current pregnancy before enrollment (19% vs. 28%). Most women were African, 
young (median age, 26 years), and asymptomatic (97% had World Health Organization 
[WHO] had clinical stage 1 HIV infection). At screening, the median CD4 count was 530 
cells per cubic millimeter, and 3% of the women were HBsAg-positive.
EFFICACY AND HIV-FREE SURVIVAL RESULTS (THROUGH WEEK 1 AFTER DELIVERY)
The rate of early transmission was significantly lower in the combined maternal ART groups 
than in the zidovudine-alone group (0.5% vs. 1.8%; difference, −1.3 percentage points; 
repeated confidence interval, −2.1 to −0.4; no significant heterogeneity in subgroup 
analyses) (Table 2). The rate of infant HIV-free survival through week 1 was significantly 
higher (i.e., the rate of early transmission or death was significantly lower) with zidovudine-
based ART than with zidovudine alone (periods 1 and 2) (Fig. 2A) or tenofovir-based ART 
(period 2) (Fig. 2B).
SAFETY RESULTS IN THE ANTEPARTUM COMPONENT
Maternal Adverse Events—During periods 1 and 2, women receiving zidovudine-based 
ART had a significantly higher rate of any grade 2 or higher adverse event than those 
receiving zidovudine alone (21.1% vs. 17.3%, P = 0.008) and a higher rate of grade 2 or 
higher abnormal blood chemical values (primarily elevations in the alanine aminotransferase 
level) (5.8% vs. 1.3%, P<0.001) (Table 3, and Table S2 in the Supplementary Appendix). 
During period 2, women receiving tenofovir-based ART had a significantly higher rate of 
grade 2 or higher abnormal blood chemical values than those receiving zidovudine alone 
(2.9% vs. 0.8%, P = 0.03), but there was no significant difference between the two ART 
groups (P = 0.26). Grade 2 or higher elevations in the creatinine level occurred in less than 
1% of women in all groups. Table S3 in the Supplementary Appendix provides additional 
details on signs, symptoms, and diagnoses. There were no maternal deaths. The rate of trial-
drug discontinuation was low (2 to 5%) and did not differ significantly among the three 
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groups; 4% of the women (120 of 3248) discontinued their assigned antiretroviral regimen 
prematurely, and 0.7% had a discontinuation that was assessed as being possibly related to a 
trial drug.
Adverse Pregnancy Outcomes—During periods 1 and 2, women receiving zidovudine-
based ART had significantly higher rates than women receiving zidovudine alone of adverse 
pregnancy outcomes (40.0% vs. 27.5%, P<0.001), a low birth weight of less than 2500 g 
(23.0% vs. 12.0%, P<0.001), and preterm delivery before 37 weeks (20.5% vs. 13.1%, 
P<0.001) (Table 3; Table S2 in the Supplementary Appendix provides additional details on 
the combined outcome of low birth weight and preterm delivery and the combined outcome 
of very low birth weight and very preterm delivery). During period 2, women receiving 
tenofovir-based ART had significantly higher rates than women receiving zidovudine alone 
of adverse outcomes (34.7% vs. 27.2%, P = 0.04) and a low birth weight of less than 2500 g 
(16.9% vs. 8.9%, P = 0.004), but there was no significant difference for any outcome 
between the two ART groups. No significant differences in stillbirth or spontaneous abortion 
and congenital anomalies were observed among the three groups (Table S4 in the 
Supplementary Appendix lists congenital anomalies).
With respect to severe pregnancy outcomes, no significant differences were observed for the 
composite or individual outcomes between women receiving zidovudine-based ART and 
those receiving zidovudine alone (periods 1 and 2). During period 2, no significant 
differences between tenofovir-based ART and zidovudine alone were observed for 
composite or individual outcomes. However, women receiving tenofovir-based ART had 
significantly higher rates than those receiving zidovudine-based ART of severe adverse 
pregnancy outcomes (9.2% vs. 4.3%, P = 0.02) and very preterm delivery before 34 weeks 
(6.0% vs. 2.6%, P = 0.04); in the group assigned to zidovudine-based ART, 80% of very 
preterm deliveries occurred during period 1, with only 20% during period 2.
Infant Safety Outcomes—Among 3202 live births, no significant differences were 
observed in pairwise comparisons of the groups for composite or individual infant adverse 
outcomes other than death (Table 3, and Tables S5 and S6 in the Supplementary Appendix). 
There were 60 infant deaths (1.9% of live births) by week 1 (Table 3; Table S7 in the 
Supplementary Appendix lists reported causes). No significant difference in infant deaths 
was observed between the group assigned to zidovudine-based ART and the zidovudine-
alone group (periods 1 and 2) (1.2% and 2.0%, respectively; P = 0.13). During period 2, no 
significant difference in infant deaths was observed between the group assigned to tenofovir-
based ART and the zidovudine-alone group (4.4% and 3.2%, respectively; P = 0.43), but the 
group assigned to tenofovir-based ART had significantly more infant deaths than the group 
assigned to zidovudine-based ART (4.4% vs. 0.6%, P<0.001). However, of 17 deaths in the 
group assigned to zidovudine-based ART, 88% (15 deaths) occurred during period 1 and 
only 12% (2 deaths) during period 2. A post hoc analysis suggested that mortality by week 1 
was highest among very preterm infants (27.0%), with lower mortality rates among those 
born at a gestational age of 34 to less than 37 weeks (3.3%) and those born at term (0.5%).
Fowler et al. Page 7
N Engl J Med. Author manuscript; available in PMC 2017 May 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
DISCUSSION
The PROMISE trial showed the efficacy of triple-drug ART for preventing transmission 
among HIV-infected pregnant women with high CD4 counts. All three regimens studied had 
a transmission rate of less than 2%, but the ART regimens had significantly lower rates of 
transmission than zidovudine alone (0.5% vs. 1.8%). However, both ART regimens were 
associated with higher rates of adverse events than zidovudine alone.
Maternal grade 2 or higher laboratory abnormalities were more common with zidovudine-
based ART (periods 1 and 2) and tenofovir-based ART (period 2) than with zidovudine 
alone. However, no significant difference between the two ART regimens was observed. 
Specifically, there were no increases in hematologic toxic effects with zidovudine-based 
ART or renal toxic effects with tenofovir-based ART, and there were no maternal deaths. 
Rates of trial-drug discontinuation due to toxic effects were low.
Higher rates of adverse pregnancy outcomes were observed with zidovudine-based ART 
(periods 1 and 2) and tenofovir-based ART (period 2) than with zidovudine alone, but no 
significant difference between the two ART regimens was observed. Our results are 
consistent with those of observational studies in Africa that controlled for CD4 count and 
showed higher rates of pre-term delivery and low birth weight among women initiating ART 
(primarily nevirapine-based) during pregnancy than among those starting zidovudine plus 
single-dose nevirapine.5,6 In resource-limited settings, preterm delivery and low birth weight 
can be associated with increased morbidity and increased newborn or later postnatal 
mortality.8–11
Reassuringly, the rate of very preterm delivery did not differ significantly between the 
zidovudine-alone group and the group assigned to zidovudine-based ART (periods 1 and 2) 
or the group assigned to tenofovir-based ART (period 2). However, the rate of very preterm 
delivery differed significantly between the two ART groups during period 2 (2.6% with 
zidovudine-based ART vs. 6.0% with tenofovir-based ART, P = 0.04), as did early infant 
mortality (correlated with very pre-term delivery) (0.6% vs. 4.4%, P<0.001). This resulted in 
a significantly higher rate of HIV-free survival among infants in the group assigned to 
zidovudine-based ART than among those in the group assigned to tenofovir-based ART 
during period 2 (but no significant difference between infants in the group assigned to 
tenofovir-based ART and those in the zidovudine-alone group).
The reason for differences in very preterm delivery and infant mortality between the two 
ART groups is unclear. Comparisons are limited to concurrent randomization during period 
2. Overall, 40 of 101 very preterm deliveries (40%) and 28 of 60 infant deaths (47%) 
occurred during period 2. However, in the group assigned to zidovudine-based ART, 80% of 
very preterm deliveries and 88% of infant deaths occurred during period 1. This suggests 
there could be some unknown confounder resulting in lower rates of very preterm delivery 
and infant death in the group assigned to zidovudine-based ART during period 2. A study in 
Botswana that compared birth outcomes in women receiving tenofovir-based ART (with 
efavirenz) or zidovudine-based ART (primarily with nevirapine) showed no significant 
differences in preterm delivery or stillbirth.12 A potential biologic cause may be a 
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pharmacokinetic interaction between lopinavir–ritonavir and tenofovir; decreased renal 
clearance of tenofovir and increased plasma and intracellular levels, particularly in women, 
have been reported with concomitant administration.13–15 In the PROMISE trial, the 
lopinavir–ritonavir dose was increased during the third trimester because pharmacokinetic 
studies showed decreased lopinavir–ritonavir levels with standard doses in late 
pregnancy.16,17
The ART regimens in the PROMISE trial were protease inhibitor–based because nevirapine-
based ART was contraindicated in women with a CD4 count of more than 250 cells per 
cubic millimeter, and efavirenz, the other available nonnucleoside reverse-transcriptase 
inhibitor (NNRTI), was contraindicated in pregnancy at that time. There are inconsistent 
findings regarding protease inhibitor–based ART and preterm delivery.3,18–21 Some studies 
have shown that protease inhibitors reduce progesterone production in the trophoblast in 
vitro and that low progesterone levels are associated with preterm delivery.22–25 However, 
other studies have shown that nevirapine-based ART is also associated with a higher rate of 
preterm delivery than zidovudine plus single-dose nevirapine.5,6 The PROMISE trial was not 
designed to compare protease inhibitor–based ART with NNRTI-based ART, and we cannot 
comment on whether the current WHO-recommended ART regimen of tenofovir, 
emtricitabine, and efavirenz would be associated with a lower risk of low birth weight or 
preterm delivery than the ART regimens in the PROMISE trial. However, the Botswana data 
are reassuring in that the combination of tenofovir, emtricitabine, and efavirenz was not 
associated with higher rates of adverse pregnancy outcomes than zidovudine-based ART.12
In conclusion, the PROMISE trial showed superior efficacy of triple-drug ART, as compared 
with zidovudine plus single-dose nevirapine, for the prevention of mother-to-child 
transmission in HIV-infected women with high CD4 cell counts but also showed higher rates 
of adverse events. On the basis of recent trials, the WHO recommends ART for HIV-infected 
persons regardless of CD4 cell count, and there are clear benefits of ART for the prevention 
of mother-to-child transmission and maternal health.26,27 However, it is also clear that the 
most efficacious and safest triple-drug ART regimens during pregnancy remain to be 
defined. Our findings emphasize the need for continued research to assess ART in pregnancy 
to ensure safer pregnancies for HIV-infected women and healthier outcomes for their 
uninfected infants.
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Figure 1. Randomization Schema and Drug Regimens during the Antepartum Component of the 
Trial
Under version 2.0 of the trial protocol (period 1), owing to limited safety data on tenofovir 
in pregnancy, only women who were positive for hepatitis B surface antigen could be 
randomly assigned to tenofovir-based antiretroviral therapy (ART); under version 3.0 
(period 2), all women could be assigned to any of the three regimens. Infants received once-
daily nevirapine in all trial groups, with dosing based on birth weight, from birth through 6 
weeks of age. All women and infants received prophylaxis with trimethoprim–
sulfamethoxazole. All women who met specific treatment guidelines and all infants who 
were confirmed to be infected with the human immunodeficiency virus (HIV) began ART 
immediately. Infants of women coinfected with hepatitis B and HIV received hepatitis B 
immune globulin and hepatitis B vaccine at birth and the full hepatitis B vaccine series.
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Figure 2. Probability of Infant HIV Infection or Death through the Week 1 Postpartum Visit (6 
to 14 Days after Delivery)
The insets show the same data on an expanded y axis. TDF denotes tenofovir, TDF-based 
ART tenofovir, emtricitabine, and lopinavir–ritonavir, ZDV zidovudine, ZDV alone 
zidovudine plus single-dose nevirapine, and ZDV-based ART zidovudine, lamivudine, and 
lopinavir–ritonavir.
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